---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041878"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:07:52.091110+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M

## Summary
- Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.
- Cash burn $16.5M ($10.1M ex one-time); cash & securities $43.9M as of Sept 30, 2023.
- FY2025 revenue guidance $12M-$16M; submitted PMA supplement for cardiac surgery; CE Mark expected H1 2024.
- Beyond Cancer presented positive first-in-human UNO data at SITC; VCAP trial underway, data mid-2024.
- Agreement with Getz Healthcare for Asia-Pacific; Vizient Innovative Technology contract awarded.

## SEC filing metadata
- accession: 0001493152-23-041878
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/0001493152-23-041878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041878
- JSON: https://secwatch.observer/filing/0001493152-23-041878.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041878.txt

## Key facts
- Earnings Releases
  Beyond Air, Inc. reported fiscal quarter ended September 30, 2023 results: revenue $0.24 million, net income ($16.2) million, EPS ($0.51) per share, basic and diluted.
  - Period: fiscal quarter ended September 30, 2023
  - Revenue: $0.24 million
  - Net income: ($16.2) million
  - EPS: ($0.51) per share, basic and diluted
  - Result: reported results
  source text: first-in-human study for treatment of ASD in 2025 2 Financial Results for the Fiscal Quarter Ended September 30, 2023 Revenues for the three months ended September 30, 2023 were $0.24 million compared to zero for the quarter ended September 30, 2022. Cost of revenue of $0.4 million was recognized for the three months ended September 30, 2023, compared to $0.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/0001493152-23-041878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.